Home > Insider Trading > Filing (0001209191-22-016484)

Filing Details

Accession Number:: 0001209191-22-016484
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-03-04 19:22:41
Reporting Period:: 2020-02-18

Accepted Time:: 2022-03-04 19:22:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1628171	Revolution Medicines Inc.	RVMD	Biological Products, (No Disgnostic Substances) (2836)	472029180

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1776412	Thilo Schroeder	C/O Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-02-18	2,118,214	$0.00	2,118,214	No	4	C	Indirect	By Nextech V Oncology S.C.S., SICAV-SIF
Common Stock	Acquisiton	2020-02-18	400,000	$17.00	2,518,214	No	4	P	Indirect	By Nextech V Oncology S.C.S., SICAV-SIF
Common Stock	Acquisiton	2020-07-13	150,000	$26.00	2,668,214	No	4	P	Indirect	By Nextech V Oncology S.C.S., SICAV-SIF
Common Stock	Acquisiton	2021-02-08	300,000	$45.00	300,000	No	4	P	Indirect	By Nextech VI Oncology SCSp
Common Stock	Acquisiton	2022-03-02	116,290	$18.94	116,290	No	4	P	Indirect	By Nextech Crossover I SCSP
Common Stock	Acquisiton	2022-03-03	54,764	$18.42	171,054	No	4	P	Indirect	By Nextech Crossover I SCSP
Common Stock	Acquisiton	2022-03-03	10,873	$19.13	181,927	No	4	P	Indirect	By Nextech Crossover I SCSP
Common Stock	Acquisiton	2022-03-04	56,300	$17.69	238,227	No	4	P	Indirect	By Nextech Crossover I SCSP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Nextech V Oncology S.C.S., SICAV-SIF
No	4	P	Indirect	By Nextech V Oncology S.C.S., SICAV-SIF
No	4	P	Indirect	By Nextech V Oncology S.C.S., SICAV-SIF
No	4	P	Indirect	By Nextech VI Oncology SCSp
No	4	P	Indirect	By Nextech Crossover I SCSP
No	4	P	Indirect	By Nextech Crossover I SCSP
No	4	P	Indirect	By Nextech Crossover I SCSP
No	4	P	Indirect	By Nextech Crossover I SCSP

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-02-18	1,569,539	$0.00	1,569,539	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-02-18	548,675	$0.00	548,675	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering.
Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares,except to the extent of any pecuniary interest therein.
Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares,except to the extent of any pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.62 to $19.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.03 to $18.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.05 to $19.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.25 to $18.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.